Skip to main content

We’ve updated our Terms & Conditions and Privacy Policy. By using this site, you agree to these terms.

Meta-analysis shows similar genetic diagnostic yield for cerebral palsy and other neurodevelopmental disorders

DANVILLE, Pa. – A Geisinger meta-analysis of recent research on the genetics of cerebral palsy (CP) provides evidence that genetic testing should be offered as the standard of care for people with the disorder, similar to current recommendations for individuals with other neurodevelopmental disorders (NDD). The findings were published Tuesday in JAMA Pediatrics

Individual cases of CP—a condition that affects movement, balance and posture—have often been attributed to birth asphyxia, although recent studies show that asphyxia accounts for less than 10% of cases. A growing body of evidence suggests that a significant proportion of CP is caused by genetic changes, as is the case in other NDD like intellectual disability and autism spectrum disorder.

Sequencing of the whole genome—all genetic information in the body—or the exome—the genome’s protein-coding regions—is a standard diagnostic test for people with NDD. However, this recommendation does not currently include CP, so people with the disorder may not be offered genetic testing unless they also have a NDD.

The Geisinger research team evaluated 13 studies published between 2013 and 2022, comprising 2,612 people, related to CP and genetic testing. Their analysis found that the genetic diagnostic yield—the proportion of cases with a genetic change that accounts for the disorder—in CP is similar to that of other NDD. This finding supports including CP as one of the NDD clinical diagnoses for which genetic testing is currently recommended as part of clinical care. 

“Waiting for a co-occurring diagnosis of intellectual disability or autism in an individual with cerebral palsy to consider genetic testing is a missed opportunity to improve clinical outcomes,” said Andres Moreno De Luca, M.D., M.B.A, physician-scientist and clinical neuroradiologist at Geisinger. “Since motor disorders like cerebral palsy can be identified earlier than other neurodevelopmental disorders, genetic testing for people with cerebral palsy may allow for quicker identification of genetic changes and facilitate early interventions and potential treatment.”
 

About Geisinger
Geisinger is committed to making better health easier for the more than 1 million people it serves. Founded more than 100 years ago by Abigail Geisinger, the system now includes 10 hospital campuses, a health plan with more than half a million members, a research institute and the Geisinger College of Health Sciences, which includes schools of medicine, nursing and graduate education. With more than 25,000 employees and 1,700+ employed physicians, Geisinger boosts its hometown economies in Pennsylvania by billions of dollars annually. Learn more at geisinger.org or connect with us on Facebook, Instagram, LinkedIn and Twitter.

 
Geisinger Logo

For media inquiries:

Ashley Andyshak Hayes
Marketing Strategist
Marketing & Communications

570-271-8081
arandyshakhayes@geisinger.edu

Content from General Links with modal content